Format

Send to

Choose Destination
Breast. 2019 Dec;48:89-97. doi: 10.1016/j.breast.2019.09.011. Epub 2019 Sep 19.

Randomized controlled trial of cryotherapy to prevent paclitaxel-induced peripheral neuropathy (RU221511I); an ACCRU trial.

Author information

1
Department of Oncology, Mayo Clinic, 200 First Street SW, Rochester, MN, 55905, USA. Electronic address: Ruddy.kathryn@mayo.edu.
2
Department of Biostatistics, Mayo Clinic, 200 First Street SW, Rochester, MN, 55905, USA.
3
Department of Dermatology, Memorial Sloan Kettering Cancer Center, 1275 York Ave., New York, NY, 10065, USA.
4
Inova Hematology Oncology, 8501 Arlington Blvd., Suite 340, Fairfax, VA, 22031, USA.
5
Marshfield Clinic - Weston Center, 3501 Cranberry Blvd., Weston, WI, 54476, USA.
6
Cancer and Hematology Centers of Western Michigan, 145 Michigan St. NE, #3100, Grand Rapids, MI, 49503, USA.
7
Carle Cancer Center, 509 W. University Ave., Urbana, IL, 61801, USA.
8
Department of Oncology, Mayo Clinic, 200 First Street SW, Rochester, MN, 55905, USA.

Abstract

PURPOSE:

This pilot trial aimed to assess if cooling hands and feet with crushed ice during receipt of paclitaxel helps prevent peripheral neuropathy.

METHODS:

This prospective, randomized trial compared cryotherapy to standard care in patients initiating paclitaxel weekly x 12. For those on cryotherapy, hands and feet were cooled starting 15 min prior to and ending 15 min after each paclitaxel dose. EORTC QLQ-CIPN20 was completed at baseline, weekly x12, then monthly x6. Area under the curve (AUC) was calculated for subscale scores, adjusting for baseline, and compared between arms (Wilcoxon rank-sum test). Cross-study comparisons used data from 2 prior similarly-conducted neuropathy trials.

RESULTS:

Forty-six patients were accrued. Three withdrew and one was ineligible. Of the remaining 42 (21 cryotherapy, 21 control), 39 (19 cryotherapy, 20 control) were analyzable for AUC. Cryotherapy was well tolerated, but the AUC of the CIPN20 sensory scores over 12 weeks of paclitaxel was not found to differ between the study arms (mean difference 3.45, 95% CI -3.13 to 10.02, p = 0.26). However, the control arm of the current trial experienced less neuropathy than did the placebo arms of two previous similar trials. When our cryotherapy arm was compared to the combined control arms from all three trials, the cryotherapy arm had less neuropathy (Wilcoxon Rank-Sum p = 0.01).

CONCLUSION:

While there was no difference in CIPN20 scores identified between the 2 study arms in the current phase II trial, further investigation is needed given that the control arm experienced less neuropathy than was expected.

KEYWORDS:

Chemotherapy-induced neuropathy; Cryotherapy; Paclitaxel acute pain syndrome; Paclitaxel-associated neuropathy

Supplemental Content

Full text links

Icon for Elsevier Science
Loading ...
Support Center